hs-10516
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 25, 2023 (NCT06049030)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07239596 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07097935 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06553339 | Phase 1 | Jul 19, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Peking University |
| NCT06049030 | Phase 1 | Sep 25, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Peking University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2023 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1